凯信远达上涨2.96%，报1.565美元/股，总市值2424.60万美元

Group 1 - The core viewpoint of the article highlights the financial performance and upcoming reporting of CASI Pharmaceuticals, indicating a significant revenue growth but a net loss [1][2][3] Group 2 - As of July 30, CASI's stock opened at $1.565 per share, with a market capitalization of $24.246 million [1] - For the fiscal year ending March 31, 2025, CASI reported total revenue of $6.24 million, representing an 83.04% year-over-year increase [1] - The company's net profit attributable to shareholders was a loss of $10.75 million, which is a 12.83% decrease compared to the previous year [1] - CASI Pharmaceuticals is a Nasdaq-listed biopharmaceutical company focused on providing advanced treatment solutions for blood cancers in China, with headquarters in Rockville, Maryland, and subsidiaries in Beijing and Wuxi [2] - The company's product and research pipeline includes treatments for multiple myeloma, B-cell non-Hodgkin lymphoma, and acute lymphoblastic leukemia [2] - CASI is scheduled to disclose its mid-year report for the fiscal year 2025 on August 15, with the actual date subject to company announcements [2]